Pluri (NASDAQ:PLUR) Shares Climb 5.1% – Should You Buy?

Posted by Stanley Muller on Oct 9th, 2026

Pluri Inc. (NASDAQ:PLUR – Get Free Report)’s share price was up 5.1% during trading on Wednesday. The company traded as high as $1.04 and last traded at $1.04. 61,505 shares were traded during mid-day trading, an increase of 267% from the average daily volume of 16,741 shares. The stock had previously closed at $0.99.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Pluri has an average rating of “Sell”.

Get Our Latest Stock Report on PLUR

Pluri Trading Down 4.7%

The company has a market cap of $12.02 million, a price-to-earnings ratio of -0.39 and a beta of 0.69. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $2.19.

Pluri (NASDAQ:PLUR – Get Free Report) last released its quarterly earnings data on Thursday, September 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.66 million.

About Pluri

(Get Free Report)

Pluri Inc (NASDAQ: PLUR), formerly known as Pluristem Therapeutics, is a biotechnology company developing cell-based products using its proprietary three-dimensional cell expansion platform. The company’s technology is designed to produce large quantities of allogeneic cells, which are cells intended for use in patients other than the original donor, without requiring a tissue match.

Pluri’s research has focused primarily on placenta-derived stromal cells, marketed under the PLX platform.